V. Michael Whitehead

1.5k total citations
37 papers, 1.2k citations indexed

About

V. Michael Whitehead is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Molecular Biology. According to data from OpenAlex, V. Michael Whitehead has authored 37 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Public Health, Environmental and Occupational Health, 18 papers in Hematology and 10 papers in Molecular Biology. Recurrent topics in V. Michael Whitehead's work include Acute Lymphoblastic Leukemia research (25 papers), Acute Myeloid Leukemia Research (10 papers) and Chronic Myeloid Leukemia Treatments (9 papers). V. Michael Whitehead is often cited by papers focused on Acute Lymphoblastic Leukemia research (25 papers), Acute Myeloid Leukemia Research (10 papers) and Chronic Myeloid Leukemia Treatments (9 papers). V. Michael Whitehead collaborates with scholars based in Canada, United States and Vietnam. V. Michael Whitehead's co-authors include JJ Shuster, A. D. Beaulieu, A. Thomas Look, David S. Rosenblatt, John Akabutu, Matthias Dupont, SJ Lauer, Timothy A. Garrow, AJ Carroll and Barry Shane and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

V. Michael Whitehead

37 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
V. Michael Whitehead Canada 18 595 465 403 276 259 37 1.2k
Jacob Baram United States 12 329 0.6× 321 0.7× 203 0.5× 215 0.8× 107 0.4× 16 1.1k
Katharine H. Dixon United States 8 144 0.2× 360 0.8× 84 0.2× 304 1.1× 98 0.4× 8 876
Sven‐Aage Killmann Denmark 17 198 0.3× 284 0.6× 432 1.1× 136 0.5× 44 0.2× 39 848
Eduard H. Panosyan United States 14 470 0.8× 418 0.9× 70 0.2× 73 0.3× 331 1.3× 31 1.0k
Ilan Ifergan Israel 18 136 0.2× 390 0.8× 86 0.2× 251 0.9× 142 0.5× 20 1.1k
Krishnendu Roy United States 13 95 0.2× 762 1.6× 85 0.2× 212 0.8× 38 0.1× 24 1.1k
Sonia Chiasson Canada 13 321 0.5× 322 0.7× 87 0.2× 198 0.7× 193 0.7× 15 847
Cecilia Fu United States 16 380 0.6× 404 0.9× 190 0.5× 49 0.2× 340 1.3× 32 945
Ruud Oerlemans Netherlands 13 75 0.1× 583 1.3× 305 0.8× 153 0.6× 106 0.4× 23 1.2k
Susan Walther United States 11 84 0.1× 245 0.5× 45 0.1× 114 0.4× 131 0.5× 17 693

Countries citing papers authored by V. Michael Whitehead

Since Specialization
Citations

This map shows the geographic impact of V. Michael Whitehead's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Michael Whitehead with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Michael Whitehead more than expected).

Fields of papers citing papers by V. Michael Whitehead

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Michael Whitehead. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Michael Whitehead. The network helps show where V. Michael Whitehead may publish in the future.

Co-authorship network of co-authors of V. Michael Whitehead

This figure shows the co-authorship network connecting the top 25 collaborators of V. Michael Whitehead. A scholar is included among the top collaborators of V. Michael Whitehead based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Michael Whitehead. V. Michael Whitehead is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Whitehead, V. Michael. (2006). Acquired and inherited disorders of cobalamin and folate in children. British Journal of Haematology. 134(2). 125–136. 96 indexed citations
2.
3.
4.
5.
Graham, Michael L., Jonathan J. Shuster, B A Kamen, et al.. (1996). Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: a pediatric oncology group study.. PubMed. 2(2). 331–7. 14 indexed citations
6.
Baruchel, Sylvain, Mark L. Bernstein, V. Michael Whitehead, et al.. (1995). A Phase I study of acivicin in refractory pediatric solid tumors. Investigational New Drugs. 13(3). 211–215. 10 indexed citations
7.
Bernstein, Mark L., V. Michael Whitehead, Holcombe E. Grier, et al.. (1993). Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood: A pediatric oncology group study. Cancer. 72(5). 1790–1794. 4 indexed citations
8.
Bernstein, Mark L., V. Michael Whitehead, Holcombe E. Grier, et al.. (1993). A phase I trial of fazarabine in refractory pediatric solid tumors. Investigational New Drugs. 11(4). 309–312. 8 indexed citations
9.
Ochs, J, Martin L. Brecher, Donald H. Mahoney, et al.. (1991). Recombinant interferon alfa given before and in combination with standard chemotherapy in children with acute lymphoblastic leukemia in first marrow relapse: a Pediatric Oncology Group pilot study.. Journal of Clinical Oncology. 9(5). 777–782. 15 indexed citations
10.
Bell, Beverly, Harry W. Findley, J. Krischer, et al.. (1991). Phase II Study of 13-cis-Retinoic Acid in Pediatric Patients with Acute Nonlymphocytic Leukemia—A Pediatric Oncology Group Study. Journal of Immunotherapy. 10(2). 77–83. 9 indexed citations
11.
Dubowy, Ronald L., Yaddanapudi Ravindranath, Carlos S. Alvarado, et al.. (1990). Phase II Trial of Trimetrexate in the Treatment of Recurrent Childhood Acute Lymphoblastic Leukemia: A pediatric Oncology Group Study. JNCI Journal of the National Cancer Institute. 82(20). 1641–1642. 14 indexed citations
12.
Green, Daniel M., Jeffrey P. Krischer, Beverly Bell, et al.. (1990). Phase I study of a 120‐hour continuous intravenous infusion of 5‐fluorouracil in pediatric patients with recurrent solid tumors: A pediatric oncology group study. Medical and Pediatric Oncology. 18(4). 321–324. 7 indexed citations
13.
Whitehead, V. Michael, Mark L. Bernstein, Roger A. Vega, et al.. (1990). Phase I trial of indicine-N-oxide in children with leukemia and solid tumors: a Pediatric Oncology Group study. Cancer Chemotherapy and Pharmacology. 26(5). 377–379. 9 indexed citations
14.
Whitehead, V. Michael, B A Kamen, & A. D. Beaulieu. (1987). Levels of Dihydrofolate Reductase in Livers of Birds, Animals, Primates, and Man. PubMed. 4(3). 185–189. 15 indexed citations
15.
Kamen, B A, et al.. (1985). Lack of Dihydrofolate Reductase in Human Tumor and Leukemia Cells In Vivo. PubMed. 2(2). 133–138. 30 indexed citations
16.
Esseltine, Dixie W., Carolyn Freeman, Louise Chevalier, et al.. (1981). Computed tomography brain scans in long term survivors of childhood acute lymphoblastic leukemia. Medical and Pediatric Oncology. 9(5). 429–438. 26 indexed citations
17.
Freeman, Carolyn, et al.. (1980). Retinoblastoma: The case for radiotherapy and for adjuvant chemotherapy. Cancer. 46(9). 1913–1918. 25 indexed citations
18.
Freeman, Carolyn, et al.. (1980). Osteogenic sarcoma following treatment with megavoltage radiation and chemotherapy for bone tumors in children. Medical and Pediatric Oncology. 8(4). 375–382. 9 indexed citations
19.
Rosenblatt, David S., et al.. (1978). Synthesis of Methotrexate Polyglutamates in Cultured Human Cells. Molecular Pharmacology. 14(1). 210–214. 49 indexed citations
20.
Rosenblatt, David S., et al.. (1978). Prolonged Inhibition of DNA Synthesis Associated with the Accumulation of Methotrexate Polyglutamates by Cultured Human Cells. Molecular Pharmacology. 14(6). 1143–1147. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacob Baram Breakdown of academic impact, for papers by Katharine H. Dixon Breakdown of academic impact, for papers by Sven‐Aage Killmann Breakdown of academic impact, for papers by Eduard H. Panosyan Breakdown of academic impact, for papers by Ilan Ifergan Breakdown of academic impact, for papers by Krishnendu Roy Breakdown of academic impact, for papers by Sonia Chiasson Breakdown of academic impact, for papers by Cecilia Fu Breakdown of academic impact, for papers by Ruud Oerlemans Breakdown of academic impact, for papers by Susan Walther
Rankless by CCL
2026